AGEN
AGEN
Positions held
Your positionsAGEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination
2026-10-03 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
2026-09-28 · Agenus Shares Rise After Chardan Initiates Coverage at Buy
2026-09-20 · Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
2026-09-10 · Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
2026-08-31 · Agenus to Participate in Upcoming September Investor Conferences
2026-08-16 · Agenus (AGEN) Stock Fair Value Falls After Analysts Rework Pipeline And Financing Assumptions
Price (daily)
Full chart · RSI · MACD · patterns